OS Therapies Prepares for J.P. Morgan Conference, Showcasing OST-HER2's Potential in Pediatric Oncology

OS Therapies Prepares for Key Presentation at J.P. Morgan Healthcare Conference

OS Therapies, Inc., a clinical-stage biotechnology company specializing in immunotherapies and targeted drug conjugates for cancer treatment, readies for a significant opportunity at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. Scheduled from January 13-16, 2025, in San Francisco, this event is a premier gathering for industry leaders, innovative firms, and investors in the healthcare sector. Paul Romness, the Chair and CEO of OS Therapies, expresses enthusiasm about the company's participation, especially following its successful IPO in 2024. The conference serves as an essential platform for OS Therapies to engage with institutional investors and enhance its visibility in the capital markets.

A focal point of OS Therapies' presentation will be the pivotal Phase 2b clinical trial of OST-HER2, a targeted therapy designed to treat recurrent, resected metastatic Osteosarcoma, which is a rare form of pediatric cancer. Romness emphasizes the trial's importance, as the company anticipates a potential approval by 2025. Such approval could have transformative implications for families impacted by this disease, offering new hope for treatment options. Additionally, the approval may qualify OS Therapies for a Priority Review Voucher (PRV) from the U.S. FDA, valued at approximately $150 million, which can be sold or transferred to support further clinical development of OST-HER2 for other HER2-positive cancers, including breast and colorectal cancer.

While OS Therapies faces challenges due to the recent failure to reauthorize the PRV program for pediatric cancers in Congress, Romness remains optimistic about the company's prospects. He highlights that OST-HER2 has already received Rare Pediatric Disease Designation from the FDA, reinforcing the potential impact of the drug on treating childhood cancers. The market for PRVs is becoming increasingly competitive, with the latest recorded sale reaching $150 million, signaling a growing interest in these valuable incentives. As OS Therapies prepares for the healthcare conference, the company's commitment to advancing treatment options for rare diseases remains steadfast, promising a hopeful future for young patients and their families.

In addition to its clinical advancements, OS Therapies looks to capitalize on the growing interest in pediatric cancer treatments. The company's strategic engagement at the J.P. Morgan Healthcare Conference could enhance its relationships with investors, ultimately fostering further innovation in the field of oncology. With a focus on rare diseases, OS Therapies is positioned to make a significant impact within the biotech landscape, particularly in addressing unmet needs in pediatric oncology.